Software

By Pharma

For Pharma

A dynamic framework for evidence generation
planning and execution

DNA

DNA
WHY?
OVERVIEW
HIGHLIGHTS
OUTCOMES
DEMO

Based on decades of Pharma and strategic consulting expertise

AESARA leadership team has held industry-based executive positions within HEOR/MA from small biotech to large pharmaceutical companies.

Every input is HEOR/MA focused Everything in one place

WHY?

What do they say about the need for Integrated Evidence Planning (IEP)?

“ At earlier stages of integration, companies still develop functional evidence generation plans bottom-up, and bring those plans together into an ‘integrated’ plan later. While this is a good starting basis it does not allow for the most efficient use of resources. In addition, we notice that involvement of countries (timing and number) varies across the companies and is less systematic in terms of the involvement of smaller yet progressive countries.”

PharmExec.com

Feb 04, 2020

OVERVIEW

ATLAS framework

Strategic roadmap to go from unmet need to patient access

Preparation

Anchor to strategic positioning

Direction

Develop value proposition

Execution

Drive value & access roadmap

Analysis

Identify gaps

Preparation 

Anchor to strategic positioning

TARGET PRODUCT PROFILE

Competitive Landscape

Strategic Imperatives

Critical Success Factors

Market Access Goals

HIGHLIGHTS

Single source of truth for your value proposition and value evidence

Everything

in

ONE

place

Up to date product strategy slides on demandPowerPoint Presentation ready output

Management dashboard to view and monitor KPIsEnable leadership insights

Role-based accessControl based on roles and responsibilities

Data securityVetted and approved by multiple pharma companies

OUTCOMES

Alignment

Align and organize value messaging, available evidence and evidence generation activities

Identify data gaps to inform evidence generations planning and prioritization

Where is your product roadmap?
Map it out on ATLAS.